Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Cash Flows From Operating Activities
Net loss	$ (11,914)	$ (6,814)
Adjustments to reconcile net income to net cash
Depreciation and amortization	3,046	1,829
Realignment accrual accretion	161	147
Deferred income taxes, net	0	5
Provision for bad debt, net	58	30
Reversal of contingent consideration accrual	(1,557)	0
Non-cash loss on sale of Pharmakon	6,868	0
Stock-based compensation	1,936	1,494
Non-cash facilities realignment	0	575
Other losses and expenses, net	0	16
Other changes in assets and liabilities:
Decrease in accounts receivable	1,397	2,095
Decrease in unbilled costs	770	711
Decrease in income tax receivable	0	3,298
(Increase) decrease in other current assets	(1,797)	327
Decrease in other long-term assets	2,617	0
Increase in accounts payable	873	522
Increase in unearned contract revenue	2,465	2,625
(Decrease) increase in accrued salaries and bonus	(2,381)	4,512
Increase in accrued liabilities	1,817	5,142
Decrease in long-term liabilities	(2,374)	(162)
Net cash provided by operating activities	1,985	16,352
Cash Flows From Investing Activities
Cash paid for acquisition, net of cash acquired	0	(23,912)
Purchase of property and equipment	(343)	(2,130)
Net cash used in investing activities	(343)	(26,042)
Cash Flows From Financing Activities
Cash paid for repurchase of restricted shares	(16)	(62)
Payments for Repurchase of Common Stock	(16)	(62)
Net cash used in financing activities	(16)	(62)
Net increase (decrease) in cash and cash equivalents	1,626	(9,752)
Cash and cash equivalents – beginning	62,711	72,463
Cash and cash equivalents – ending	64,337	62,711
Cash paid for taxes	37	86
Retained Earnings [Member]
Cash Flows From Operating Activities
Net loss	$ (11,914)	$ (6,814)